US 12,138,232 B2
Compounds for treating coronavirus infection
Dorit Arad, Tel Aviv (IL)
Assigned to NLC Pharma Ltd, Bnei-Brak (IL)
Filed by NLC Pharma Ltd, Bnei-Brak (IL)
Filed on Dec. 22, 2023, as Appl. No. 18/393,798.
Application 18/393,798 is a continuation of application No. 17/887,461, filed on Aug. 14, 2022, granted, now 11,857,517.
Application 17/887,461 is a continuation of application No. PCT/IB2021/051256, filed on Feb. 15, 2021.
Claims priority of provisional application 62/976,420, filed on Feb. 14, 2020.
Prior Publication US 2024/0130983 A1, Apr. 25, 2024
Int. Cl. A61K 31/122 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01); A61K 31/198 (2006.01); A61K 31/222 (2006.01); A61K 31/381 (2006.01); A61K 31/40 (2006.01); A61K 31/422 (2006.01); A61K 31/433 (2006.01); A61K 31/454 (2006.01); A61K 31/513 (2006.01); A61K 31/536 (2006.01); A61K 36/30 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/122 (2013.01) [A61K 9/0053 (2013.01); A61K 9/0095 (2013.01); A61K 9/127 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/2095 (2013.01); A61K 9/282 (2013.01); A61K 9/2833 (2013.01); A61K 9/4833 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/198 (2013.01); A61K 31/222 (2013.01); A61K 31/381 (2013.01); A61K 31/40 (2013.01); A61K 31/422 (2013.01); A61K 31/433 (2013.01); A61K 31/454 (2013.01); A61K 31/513 (2013.01); A61K 31/536 (2013.01); A61K 36/30 (2013.01); A61P 31/14 (2018.01); A61K 2236/51 (2013.01)] 10 Claims
 
1. A pharmaceutical composition comprising:
a compound represented by Formula I:

OG Complex Work Unit Chemistry
wherein R1-R6 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic, halo, hydroxy, alkoxy, aryloxy, thiohydroxy, thioalkoxy, thioaryloxy, sulfinyl, sulfonyl, sulfonate, sulfate, cyano, nitro, azide, phosphonyl, phosphinyl, carbonyl, thiocarbonyl, a urea group, a thiourea group, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, S-thiocarbamyl, C-amido, N-amido, C-carboxy, O-carboxy, sulfonamido, guanyl, guanidinyl, hydrazine, hydrazide, thiohydrazide, and amino, or alternatively, R1 and R2 together form a five- or six-membered aromatic or aliphatic ring,
and further comprising:
a) at least one phospholipid, wherein a weight ratio of said at least one phospholipid to said compound in the composition is in a range of from 10:1 to 1:10,
and/or
b) liposomes.